Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ReT02
- Development stage
- Preclinical
- Lead developer
- Beijing Xunsheng Biomedical Research
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
ReT02 (also known as ReT-02 or ReT02 ACT) is an autologous chimeric antigen receptor-engineered tumor-infiltrating lymphocyte (CAR-TIL) cell therapy being developed by Beijing Xunsheng Biomedical Research for the treatment of advanced solid tumors. The therapy involves genetically engineering tumor-infiltrating lymphocytes (TILs) to express a chimeric antigen receptor (CAR) to enhance their targeted antitumor activity against solid tumors. ReT02 is currently in IND-enabling preclinical development, with an Investigational New Drug (IND) application expected in 2026.
Beyond the preview
Go deeper on ReT02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ReT02.